Cantex Pharmaceuticals, Inc. is a clinical stage pharmaceutical company focused on developing and commercializing proprietary pharmaceuticals that improve the treatment of cancer.

Cantex's pipeline has two product candidates in clinical development:

  • CX-01, a polysaccharide that is a new chemical entity, neutralizes the activity of proteins that play a role in the adhesion of leukemia stem cells to the protective bone marrow environment, and neutralizes the activity of platelet factor 4, a cytokine which suppresses and delays platelet recovery after chemotherapy. CX-01 recently completed a Phase IIB clinical trial for acute myeloid leukemia (AML) and, separately, a Phase II clinical trial for myelodysplastic syndrome (MDS). Cantex plans to further the development of CX-01 by initiating a Phase III clinical trial in AML in 2019.
  • Dicopp® (formerly known as CX-02), a proprietary combination of disulfiram + copper is planned to enter a Phase II clinical trial for metastatic pancreatic cancer in early 2019.

 

Latest News

Spotlight

Cantex has two product candidates in clinical development:

CX-01:

  • A new chemical entity, derived from heparin, with very low anticoagulant activity, neutralizes the activity of heparin-binding proteins that play a role in the adhesion of leukemia cells to the protective bone marrow environment and neutralizes the activity of a protein that suppresses and delays platelet recovery after chemotherapy
  • In a completed pilot study, 100% of primary AML patients achieved a complete remission from a single cycle of CX-01 combined with standard “7 + 3” induction chemotherapy
  • CX-01 has completed a randomized Phase IIB study for the induction treatment of AML in patients over age 60. In that randomized, 75-patient clinical trial, newly diagnosed AML patients received standard “7 + 3” induction chemotherapy ± CX-01
  • Cantex plans to further the development of CX-01 by initiating a Phase III clinical trial in AML in 2019
  • An encouraging overall response rate in a Phase II trial in patients with highly refractory MDS was reported at ASCO 2018
  • CX-01 has received Orphan Drug and Fast Track Designations from the FDA for the treatment of AML

Dicopp®:

  • Proprietary combination of disulfiram + copper which has been extensively reported to have cancer stem cell killing mechanisms
  • Highly cytotoxic to cancer stem cells derived from patients with pancreatic cancer
  • Phase II clinical study in metastatic pancreatic cancer is expected to be initiated in early 2019
  • Cantex owns issued and pending intellectual property for Dicopp®
  • FDA has granted Orphan Drug Designation for Dicopp® for glioblastoma; Dicopp® is a 505(b)(2)product